EMID2 is a novel biotherapeutic for aggressive cancers identified by in vivo screening.
Ambra CappellettoEdoardo AlfìNina VolfThi Van Anh VuFrancesca BortolottiGiulio CiucciSimone VodretMarco FantuzMartina PerinAndrea CollivaGiacomo RozziMatilde RossiGiulia RuoziLorena ZentilinRoman VuerichDaniele BorinRomano LapasinSilvano PiazzaMattia ChiesaDaniela LorizioLuca TriboliSandeep KumarGaia MorelloClaudio TripodoMaurizio PinamontiGiulia Maria PipernoFederica BenvenutiAlessandra RustighiHanjoong JoStefano PiccoloGiannino Del SalAlessandro CarrerMauro GiaccaSerena ZacchignaPublished in: Journal of experimental & clinical cancer research : CR (2024)
This is the first in vivo screening, precisely designed to identify proteins able to interfere with cancer cell invasiveness. EMID2 was selected as the most potent protein, in line with the emerging relevance of the tumor extracellular matrix in controlling cancer cell invasiveness and dissemination, which kills most of cancer patients.